Treatment of MM cells with T‐5224 alone did not affect the expression of IRF4 or cell viability but significantly enhanced the cytotoxicity of lenalidomide in both cell lines (Figure 6E). This evidence concerns the gene IRF4 and Miyoshi myopathy.